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Background: Minimally invasive adrenalectomy for pheochromocytoma (PCC) is a complex surgical
procedure especially because of the haemodynamic instability due to the excessive secretion of cath-
ecolamines, which may result in a considerable risk of conversion and complications.
Aim: By a multicentric retrospective study, the authors reported the results of laparoscopic adrenalec-
tomies in patients operated for adrenal pheochromocytomas with the aim of investigating the role of the
laparoscopic approach in managing adrenal disease.
Methods: Sixty patients, preoperatively treated with a selective alpha1-blocker, underwent 61 laparo-
scopic adrenalectomies for PCC smaller or larger than 6 cm e group A (6 cm), group B (>6 cm). We
compared the two groups of patients analyzing haemodynamic instability, operative time, conversion
rate, incidence of complications, length of hospital stay and medium and long-term outcomes.
Results: In 23 cases tumor was >6 cm in diameter. Average operative time was 165 min, with a 5%
conversion rate. There was no mortality and morbidity rate was 8.3%. Intraoperative hypertensive crises
were registered in 15% of patients, whereas 5/60 patients had hypotensive crises. After comparing the
two groups of patients, no statistically signiﬁcant differences in terms of haemodynamic instability,
operative time, conversion rate, morbidity and length of hospital stay were observed.
Conclusions: As a surgical treatment of pheochromocytomas, laparoscopic adrenalectomy is an effective
and safe approach, in selected cases even for PCCs >6 cm in diameter, although patients with such large
tumors may have a higher conversion rate and more intraoperative hypertensive crises. Preoperative
selective adrenergic blockade does not prevent intraoperative hypertensive crises, but by facilitating the
pharmacological management of the perioperative haemodynamic instability, may avoid the onset of
major adverse cardiovascular complications.
 2012 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Pheochromocytoma (PCC) is a rare neuroendocrine tumor, with
a prevalence ranging between 0.1% and 0.6% in patients suffering
from arterial hypertension.1 Minimally invasive adrenalectomy
(MA), which is associated with less pain, a lower morbidity rate,
a shorter hospital stay, a more rapid recovery and a better cosmeticzo).
ciates Ltd. Published by Elsevier Ltresult than “open” surgery, is the gold standard for the treatment of
adrenal tumors 6 cm in diameter and weighing <100 g.2 An
analysis of the published studies on PCC surgery, which only rarely
involve case series of more than 50 patients, shows that the mini-
mally invasive approach has signiﬁcant advantages.3 However, the
role of laparoscopy in treating PCC >6 cm in diameter is still
controversial for the presumed higher risk of malignancy and of
local recurrence rate, and moreover it may be associated with
longer operative times, a greater blood loss, a higher conversion
rate, and several complications as well. Preoperative blood pressured. All rights reserved.
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the adrenal capsule are the treatment guidelines. Provided that
there is no evidence of local invasion or of supposed malignancy,
laparoscopic adrenalectomy (LA) is successfully carried out even for
patients with PCC >6 cm in diameter, but this indication is at
present matter of debate.
We report the results of a multicentric retrospective study of 60
patients with PCC smaller or larger than 6 cm e group A (6 cm),
group B (>6 cm), who underwent LA after preoperative selective
adrenergic blockade with doxazosin. The purpose of the study was
to compare haemodynamic instability, operative time, conversion
rate, incidence of complications, length of hospital stay and
medium and long-term results in both of the groups of patients.
2. Materials and methods
This study was accomplished by four surgical centers with a wide experience in
adrenal surgery (two academic centers and two endocrine-surgery centers).
A retrospective analysis was obtained from questionnaires in which patients data
were collected, with details of the preoperative laboratory tests and diagnostic
procedures for PCC, tumor size, perioperative complications, operative time, length
of hospital stay, along with clinical, laboratory, and instrumental examinations after
a ﬁve years follow-up. The sixty patients included in the study, suffering from either
preoperative stable or paroxysmal hypertension associated with other signs or
symptoms of cathecolamine excess, underwent laparoscopic adrenalectomy and
were grouped according to the tumor size (group A6 cm; group B>6 cm) (Table 1).
Whenever malignancy was assumed, for local invasion or distant metastases,
a minimally invasive approach was contraindicated. According to Zhu et al.,4 until
blood pressure (BP) and heart rate (HR) stabilization was achieved, (BP
<160/90 mmHg for at least 24 h before surgery and HR <100 bpm), in absence of
electrocardiographic ST-T changes for at least 1 week, every patient started
a preoperative drug therapy, consisting of an alpha1-blockere doxazosin, at least 15
days before surgery, with a mean daily dose of 4.54  1.65 mg and a mean length of
therapy of 21.15  5.91 days. A beta-blocker (atenolol, 50 mg daily) was added in 6
cases with tachycardia (10%). A calcium antagonist (amlodipine besylate, 5 mg daily)
in 3 cases (5%), an angiotensin receptor blocker (valsartan, 160 mg daily) in 2 cases
(3.3%), and an angiotensin-converting enzyme inhibitor (ramipril, 10 mg daily) in 2
cases (3.3%) represented the associated preoperative drug therapy. Every patient
underwent perioperative venous thromboembolism prevention. According to J.
Varon,5 systolic blood pressure (SBP) levels 180 mmHg or diastolic blood pressure
(DBP) levels 120 mmHg were considered hypertensive crises, and levels
<90 mmHg were considered hypotensive crises. For each case anesthesia chart and
pathologic report were obtained. In 10/60 patients (16.6%), by means of blood
samples and sometimes specimen samples, a genetic study looking for mutations of
the RET protoncogene was performed. Diagnostic work-up included ultrasonog-
raphy, CT scanning with contrast agent, Magnetic Resonance Imaging (MRI), whole
body metaiodobenzylguanidine (MIBG) scintigraphy in order to conﬁrm PCC diag-
nosis, and echocardiography. Patients were discharged if they had no cardiovascular
complains or pain and had begun oral feeding. Follow-up consisted of 6-monthly,
then yearly testing of urinary metanephrine levels and abdominopelvic CT scans
with contrast agent.
2.1. Anesthesiological management
In each case, in order to expand plasma volume, intravenous volume loading
was carried out in the preoperative holding area. Patients received generalTable 1
Patients data and pheochromocytoma size.
Group A 6 cm
37 patients (61.6%)
Group B >6 cm
23 patients (38.3%)
p-value
Mean age (years) 44.16 39.56 0.03
Male patients 8 (21.6%) 13 (56.5%) 0.01
Site
right 20 (54%) 11 (47.8%) 0.7
left 18 (48.6%) 12 (52.1%)
Mean size (cm) 3.9 8.3 0.001
ASA score
1e2 23 (62.1%) 15 (65.2%) 1.0
3e4 14 (37.8%) 8 (34.7%)
Mean 24 h urinary
catecholamines
(pg/dl)
585.62 (120e1800) 751.17 (147e3490) 0.1anesthesia, with no epidural anesthesia. All operations were undertaken by oro-
tracheal intubation, without anesthetizing upper airway. Invasive arterial pressure
monitoring was routinely performed. A central venous catheter was placed before
every intervention. No pulmonary artery catheters (Swan-Ganz catheters) were
used. Haemodynamic data were recorded. Heart rate, systolic and diastolic blood
pressure were recorded before inducting anesthesia, after CO2 inﬂation, before and
after adrenalectomy. After inducing anesthesia with remifentanil (0.25 mcg/kg/min)
and propofol (2 mg/kg), cisatracurium besylate (0.2 mg/kg), which was also used as
muscle relaxant during surgery, was administered. Anesthesia was maintained with
inhalation of sevoﬂurane and nitrous oxide 50% in oxygen, supplemented with
remifentanil infusion. Intraoperative muscle relaxation was maintained with inter-
mittent boluses. Blood loss and ﬂuid volume loading during surgery were also
recorded. Intraoperative treatment of hypertensive crises consisted of intravenous
administration of nitroprusside (initial dose: 0.2 mcg/kg/min, administered by
continuous intravenous infusion; maintenance dose was titrated up to a maximum
of 10mcg/kg/min), esmolol (1mg/kg bolus dose over 30 s, followed by a 150mcg/kg/
min infusion, whenever necessary, adjusting the infusion rate as required up to
300 mcg/kg/min to maintain the desired HR and/or BP), urapidil (starting dose:
0.25e0.4 mg/kg or 25 mg; maintenance dose: 9 mg/h of continuous intravenous
infusion), clonidine (single bolus: 75e150 mg in 5 min, or by continuous infusion:
0.4e5 mg/min).
2.2. Surgery
Every adrenalectomy was performed using transperitoneal laparoscopy, with
the patient positioned in the lateral decubitus. Four trocars were inserted in the
case of a right PCC and three in the case of a left one, while one supplementary
trocar was used in 11/60 cases (18.3%). In one case of bilateral adrenalectomy, after
removing the ﬁrst gland, the patient was repositioned on the table for the second,
separate procedure. Carbon dioxide pneumoperitoneumwas kept at 12e14 mmHg.
According to “vein ﬁrst” technique, at the beginning of the operation, the main
adrenal vein was identiﬁed and divided between clips. In the cases of right PCC
>6 cm, procedure beganwith superior and lateral mobilization of the adrenal gland
to facilitate identiﬁcation of vena cava and right renal vein, followed by the section
of the main adrenal vein. In most patients adrenal gland dissection was carried out
by ultrasonic or bipolar shears. Surgical specimens were always extracted through
a mini-laparotomy at the site of a trocar, using a specimen extraction bag. A
drainage tube, usually preferred by the surgeons participating to this study, was
routinely placed and then removed after 1e2 days. Postoperatively, patients were
not routinely referred to the Intensive Care Unit. No patient received epidural
analgesia.
3. Statistical analysis
Data were expressed as mean  SEM, unless otherwise speci-
ﬁed. Statistical analysis was performed with SPSS version 11.5




Our series consisted of 60 patients, 39 women and 21 men, with
a mean age of 42.4  14.38 years, who underwent a total of 61 LAs,
between January 1998 and December 2011. No cases of preoperative
stroke were reported. Associated diseases of interest included
insulin-dependent diabetes mellitus in 13 cases (21.6%) and dilated
cardiomyopathy in 4 cases (6.6%). There was one case (1.66%) of
a genetically determined polyendocrine syndrome: multiple endo-
crine neoplasia (MEN) 2A with a triple RET mutation (634, 640,
700).6 Urinary catecholamines were elevated in 58/60 patients.
Preoperative 24-h mean concentration was 649.08  548.885 pg/dl
(n.v. ¼ 0e115 pg/dl), respectively 585.62  395.44 in group A and
751.17  740.28 in group B. Thirty cases of PCC in the right adrenal
gland, 29 in the left adrenal gland and 1 bilateral tumor were re-
ported with an average diameter of 5.6 cm (3.9 cm group Ae8.3 cm
group B) (range 2.4e11 cm). In 23/60 patients (38.3%) the tumor was
larger than 6 cm, in 37/60 (61.6%) the PCC was equal to or smaller
than 6 cm (Table 1). Preoperative treatment with doxazosinwaswell
tolerated without important side effects, allowing an efﬁcacious BP
and HR control.
Fig. 1. Relationship between PCC size and hypertensive crises (SBP >180 mmHg).
*Statistically signiﬁcant relationships between PCC size (> or 6 cm) and hypertensive
crises were not observed. SBP: systolic blood pressure (mmHg). PCC:
pheochromocytoma.
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Overall mean operative time was 165.66  70.48 min and was
similar in the two groups (Table 2). Conversion to open surgery was
necessary in 3/60 patients (5%), in one case (PCC >6 cm) due to sus-
pected inﬁltrationof renal vessels, not conﬁrmedbypathology,which
found a desmoplastic reaction, and in the remaining two cases (1 PCC
>6 cmand1 PCC<6 cm) becauseof the tenacious adhesions between
PCC and the surrounding structures, and between the right colon and
the gallbladder. Mean blood loss was 143.16  63.33 ml and was
similar in the two groups of patients (Table 2). Blood transfusionwas
required foranadrenalcapsularhemorrhage, inonecaseofPCC<6cm
in diameter. There was no mortality. Morbidity was 8.3% (5/60
patients) and consisted of one abdominal wall hematoma (group B),
one caseof delayedwoundhealing ina diabetic patient (groupA), one
serosanguineous ﬂuid collection in the suprarenal space, and treated
by US guided percutaneous drainage (group B), one pneumothorax
treated bypleural aspiration (groupA), and an infection of theurinary
tract (group A). There was no relationship between preoperative
doxazosin dose and intraoperative hypertensive crises. Thesewere of
short duration and occurred at induction of anesthesia and during
manipulation of the adrenal glands in 10/60 patients (16.6%) (Fig. 1),
with a higher incidence in patients with PCC>6 cm in diameter than
in other patients, (26% vs 18.9% p ¼ 0.4), not statistically signiﬁcant
(Table 2). At induction, 3/60 patients (5%) had paroxysmal hyperten-
sion with peaks of 180/90, 180/120 and 190/110 mmHg, with HR of
85, 90 and 110 bpm, resolved after drug therapy. Further episodes
of hypertension, with a median BP of 250/180 mmHg (range 220/
160e320/150 mmHg) and a mean HR of 99  9.41 bpm, were
observed during manipulation of adrenal glands in 7/60 patients
(11.6%), and ceased after adrenalectomy. Hypertensive crises were
not associated with any signiﬁcant complication, such as cerebral
vascular accident, pulmonary edema, myocardial infarction or
ischemia, cardiac arrhythmia and multiorgan failure, and no
postoperative mechanical ventilationwas required. Fig. 1 reports the
relationshipbetweenhypertensive crises andPCC size. ThehighestBP
levels were observed in a patient who underwent laparoscopic
adrenalectomy to remove a PCC 8 cm in diameter (320/150 mmHg),
and the 24-h preoperative urinary catecholamine concentration was
655 pg/dl. No intraoperative hypotensive episodes were observed.
4.3. Postoperative outcomes
After awakening from anesthesia, 2/60 patients (3.3%) were
hypotensive (70/40 mmHg, 80/65 mmHg) and were treated byTable 2
Perioperative results.
Group A (6 cm)
37 patients





170.54  71.99 157.82  70.45 0.7
Intraoperative blood
loss (ml)
155.67  60.98 123.04  64.55 0.4
Blood transfusion 1 (2.7%) 0 1.0
Hypertensive crises
(SBP >180 mmHg)
4/37 (18.9%) 6/23 (26%) 0.4
Hypotensive crises
(SBP <90 mmHg)
3/37 (8.1%) 2/23 (8.6%) 1.0
Mortality 0 0 1.0
Conversion to open
procedure
1/37 (2.7%) 2/23 (8.6%) 0.5
Complications 3/37 (8.1%) 2/23 (8.6%) 1.0
Hospital stay (days) 4.05  0.84 3.82  0.88
* Statistically signiﬁcant differences were not observed between the two groups of
patients.
SBP ¼ systolic blood pressure.crystalloids and hydrocortisone. On postoperative day 1, 3/60
patients (5%) had hypotension which was successfully treated in
the same way. Mean hospital stay was 3.96  0.85 days and was
similar in the two groups of patients (Table 2). One male patient,
after laparoscopic resection of a PCC<6 cm in diameter, was openly
reoperated via a posterior approach, due to disease persistence
associated with adrenal retrocaval remnants. Surgical pathology
did not report any malignancy. Testing for RET mutations identiﬁed
a triple mutation (634, 640, 700) in a 37 years old female patient
suffering from MEN 2A, but no mutations were found in other
patients. Postoperative levels of urinary catecholamines were
normal at ﬁve years follow-up (12 months e 13 years), except one
young male patient who, one year after LA, underwent “open
retroperitoneal” reoperation for disease persistence due to
remnant retrocaval glandular tissue (group B).
5. Discussion
The results of our retrospective study show that laparoscopic
adrenalectomy is an effective and safe approach, even for PCCs
>6 cm in diameter, although patients with such large tumors may
have a higher conversion rate and more intraoperative hyperten-
sive crises. We reported a low perioperative morbidity and
successful medium and long-term outcomes. Preoperative selective
adrenergic blockade with doxazosin is recommended in the
management of sporadic and hereditary forms7 because it does not
prevent intraoperative hypertensive crises, but by facilitating
pharmacological management of the perioperative haemodynamic
instability, may avoid the onset of major adverse cardiovascular
events such as myocardial infarction or ischemia, reversible
myocardial depression, stroke, pulmonary or cerebral edema,
respiratory distress syndrome and multiorgan failure. These were
not observed in our series. According to literature data we propose
a laparoscopic approach also for PCC 6e8 cm only if great care is
adopted to avoid capsular disruption and, if necessary, a prompt
conversion to open technique is cautiously considered to reduce
patient risks. Pheochromocytoma is an endocrine rare tumor,
most common in women in their 40s and 50s, with an incidence in
the United States between 2 and 8 cases per million per year.8 In
the last decade, following work-up of adrenal incidentalomas
or familial syndromes, an increasing number of patients with
G. Conzo et al. / International Journal of Surgery 11 (2013) 152e156 155
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describe PCC; 1/10 patients, mostly with a sporadic form of the
tumor, may havemalignant PCC, in 1/10 cases the tumor is bilateral,
in 1/10 extradrenal and in 1/10 familial.10,11There are hereditary
forms of PCC and extraadrenal PCC, i.e. paragangliomas (PGL), that
can be found in multiple endocrine neoplasia 2 (MEN 2), von
Hippel-Landau disease (VHL), neuroﬁbromatosis (NF), and the PCC-
PGL syndromes (PGL 1e4),12 which are generally benign and
currently under study. Pheochromocytoma occurs in 30e50% of
cases of MEN 2 and in 15e20% of cases of VHL. After the 2000s it has
been shown that MA (laparoscopic and retroperitoneoscopic) is
associated with lower morbidity and mortality rates than tradi-
tional surgery, especially because it allows to reduce postoperative
pulmonary infections and thromboembolic complications.13,14
However, there are still more risks associated with the surgical
treatment of PCC, either open or laparoscopic, in spite of lower
mortality (0.0e3.8%) and less complications (5e22%) e blood
pressure variations, intraoperative blood loss, visceral lesions, and
adverse cardiovascular events (stroke, pulmonary or cerebral
edema, myocardial infarction) e than in the past.15e19 According to
Bruynzeel, a high plasma norepinephrine concentration, tumor size
>4 cm, a high preoperative mean BP and a more pronounced
postural drop after a-blockade are risk factors of haemodynamic
instability.20 Pheochromocytoma surgery is still a challenge, espe-
cially for large lesions, because of the excessive secretion of cate-
cholamines, the extensive vascularization of this kind of tumor, the
difﬁculties in mobilization and dissection of the adrenal gland, the
tenacious adhesions to adjacent structures, often to major blood
vessels (renal vein). So the role of laparoscopic approach for
neoplasms >6 cm is still controversial. During the past decade,
increased laparoscopic experience has made possible to reduce
mortality, morbidity, conversion rates, operative time, blood loss
and the length of hospital stay also for large PCC, as reported in the
rare series of patients with tumors >6 cm in diameter, demon-
strating the efﬁcacy and safety of the laparoscopic approach
(Table 3). In case of technical difﬁculties, prompt conversion to
reduce patients risks must be recommended, as well as great care
in sparing adrenal capsule. In case of capsular disruption, open or
hand assisted approach has been suggested to prevent “iatrogenic
pheochromocytomatosis”.9 Even though Toniato observed higher
blood loss in PCC >6 cm, he concluded that PCC dimensions do not
affect surgical outcome.21 On the contrary, Kercher reported longer
operative times in 18 cases of PCC >6 cm treated during 10
years.22The risk of malignancy, which was reported to be as high as
13.4%23 and of local recurrence of laparoscopically resected tumors
were considered in the past as contraindication to laparoscopicTable 3
Results of minimally invasive adrenalectomy in patients with pheochromocytomas.
Authors Patients (number) Operative time (min)
M Gagner (’96) 23 230
MK Walz (’02) 52 116  52
DE Jaroszewski (’03) 47 140
AW Kim (’04) 26 191
KW Kercher (’05) 80 169
Y Naya (’05) 23 192.7
A Toniato (’07) 40 78
MJ Mellon (’08) 11 181.4
KA Perry (’09) PCC <6 cm 22 189
KA Perry (’09) PCC >6 cm 8 212
GY Meyer-Rochow (’09) 36 183
LN Castilho (’09) 24 126
P Nau (’10) 33 142
WT Shen (’12) 102 186
YM Carter (’12) 25 e
Present series (’12) 60 165treatment of PCC >6 cm. The deﬁnition of malignancy should be
based especially on clinical observation of metastases, which can
appear more than 5 years after surgery, and consequently follow-
up of patients who have undergone PCC surgery should therefore
last more than 10 years. Furthermore, in case of familial forms, in
which bilateral PCC is common, a lifetime follow-up is necessary.9
Nevertheless, it is important to note that PCC >6 cm in diameter
become malignant less frequently than other adrenal lesions of the
same size do, and probably size cannot itself be an absolute
contraindication for LA, provided that there is no evidence of local
invasion.24 Finally, about the role of laparoscopic surgery in large
PCC, literature is still divided between experienced endocrine
surgeons supporters9,21,24e27 and detractors.28e31 Improved peri-
operative management, advances in anesthesiology and surgery,
and a better understanding of pathophysiology have allowed
a signiﬁcant reduction in mortality and morbidity associated with
perioperative adverse cardiovascular events. Preoperative BP
management with the most common drugs e alpha blockers
(phenoxybenzamine, doxazosin), or calcium antagonists (nicardi-
pine) e do not prevent intraoperative hypertensive crises but
improve both their control and the patient postoperative haemo-
dynamic proﬁle, reducing the risk of major perioperative adverse
cardiovascular complications.4,7,19,32,33 In our experience, irre-
spective of the preoperative medical treatment, a notable peri-
operative haemodynamic instability was observed (hypertensive
crises: 13.8%; hypotensive crises: 8.3%). However, hypertensive
crises were of short duration and their intraoperative pharmaco-
logical management was immediate. Moreover, no cases of major
adverse cardiovascular complications such as myocardial infarction
or ischemia, cardiac arrhythmias, stroke, pulmonary or cerebral
edema in neither group of patients were observed, conﬁrming the
efﬁcacy of preoperative a-blockade. The reasonable operative
times, limited blood loss, lowmorbidity (8.3%), low conversion rate
(5%) and short hospital stay, observed in the study, even in cases of
a tumor size >6 cm in diameter, conﬁrm the effectiveness and
safety of LA in the surgical treatment of PCC. Provided that there is
no pre- or intraoperative evidence of local invasion, it is possible to
treat cautiously even PCC 6e8 cm in diameter by LA, and results
appear to be similar to those generally reported in the treatment of
neoplasms of a smaller size. However, it should be noted that in our
study there was a relationship between hypertensive crises,
conversion rate and PCC size >6 cm in diameter, but differences
statistically signiﬁcant were not found.
Our study has several limitations. First of all, as most published
papers in PCC surgery, it was retrospective and also multicentric,
comprising a small number of treated patients. Nevertheless, theBlood loss (ml) Conversion (%) Morbidity (%) Mortality (%)
e 0 22 0
100 0 23 0
80 11 4.8 0
276 4 23 0
97 0 7.5 0
130 4.34 0 0
100 3 2.5 0
e 1.4 10 0
68 9.1 13.6 0
130 37.5 12.5 0
e 2.7 13.9 0
e 0 16.7 0
e 12.1 6 0
e 3 13.7 0
e 0 0 0
130 5 8.3 0
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a single institution referral center, based on the laparoscopic
management of a higher number of cases.9 Moreover it must be
considered the absence of a control group of patients submitted to
“open” adrenalectomies, but this issue has beenwidely evaluated in
literature data, demonstrating the advantages of MA.3,21,34
6. Conclusions
According to our results, LA was effective and safe for most
patients with PCC without preoperative suspicion of malignancy.
Moreover, it was associated with acceptable morbidity rate, similar
to those previously reported for other adrenal diseases.14 There was
a higher incidence of hypertensive crises and of conversion to open
surgery in PCC larger than 6 cm (statistically not signiﬁcant), while
blood loss, operative time, incidence of complications and long-term
outcomes did not seem to be affected by PCC size. Preoperative
selective adrenergic blockade with doxazosin did not guarantee
haemodynamic stability but allowed an optimal pharmacological
control of hypertensive episodes. Given the difﬁculties related to the
dissection of adrenal glands and the risk of perioperative adverse
cardiovascular events, LA for patients with PCC remains a complex
procedure and great caution is needed, especially in case of large
neoplasms. Experienced multidisciplinary teams in specialized
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